Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to SunMed, and Alston & Bird is serving as legal counsel to Avanos. SunMed announced it has entered into...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Fulcrum Therapeutics on the deal. Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced its underwritten public offering of 9,615,384 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Goodwin advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of Compliancy Group, LLC. Aldrich is a growth equity firm supporting disruptive innovation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of PRIA Healthcare Management. Aldrich is a growth equity firm supporting disruptive...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
